Drug Profile
Pevonedistat - Takeda Oncology
Alternative Names: MLN-4924; MLN4924-003; Pevonedistat hydrochloride; TAK 924Latest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Case Western Reserve University; Children's Oncology Group; Eli Lilly and Company; Greehey Childrens Cancer Research Institute; Louisiana State University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Nationwide Children's Hospital; PETHEMA Foundation; Takeda Oncology; Translational Genomics Research Institute; University of Miami; University of Michigan Comprehensive Cancer Center; University of Southampton; University of Southern California; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Antirheumatics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
- Mechanism of Action NEDD 8 activating enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rheumatoid arthritis
- Discontinued Acute myeloid leukaemia; Cholangiocarcinoma; Chronic myelomonocytic leukaemia; Glioblastoma; Lymphoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-small cell lung cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours
Most Recent Events
- 09 Dec 2023 Efficacy, pharmacodynamics and adverse events data from the phase I/II trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 10 Nov 2023 Preclinical trials in Rheumatoid arthritis in USA prior to November 2023 (unspecified route)
- 10 Nov 2023 Pharmacodynamics data from preclinical studies in Rheumatoid arthritis presented at the ACR Convergence 2023 (ACR-ARP-2023)